Alto Neuroscience
ANRO
75 hedge funds and large institutions have $265M invested in Alto Neuroscience in 2024 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 36 increasing their positions, 9 reducing their positions, and 5 closing their positions.
340% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 5
300% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 9
48% more call options, than puts
Call options by funds: $10.5M | Put options by funds: $7.05M
34% more capital invested
Capital invested by funds: $199M → $265M (+$66.7M)
29% more funds holding
Funds holding: 58 → 75 (+17)
15.89% more ownership
Funds ownership: 69.2% → 85.09% (+16%)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$10.7M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$8.41M |
| 3 |
Franklin Resources
San Mateo,
California
|
+$7.29M |
| 4 |
Jennison Associates
New York
|
+$4.54M |
| 5 |
ECM
ExodusPoint Capital Management
New York
|
+$3.99M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
-$3.74M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$3.57M |
| 3 |
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University
Redwood City,
California
|
-$3.23M |
| 4 |
VM
Valor Management
Chicago,
Illinois
|
-$1.68M |
| 5 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$1.14M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AG
76
Artal Group
Luxembourg
| – | -$3.74M | -350,000 | Closed |
|
|
VM
77
Valor Management
Chicago,
Illinois
| – | -$1.68M | -157,038 | Closed |
|
78
Norges Bank
Oslo,
Norway
| – | -$820K | -76,672 | Closed |
|
79
Millennium Management
New York
| – | -$206K | -16,838 | Closed |
|
|
SO
80
STRS Ohio
Columbus,
Ohio
| – | -$17.1K | -1,600 | Closed |
|
ANRO Hedge Fund Activity: Q3 2024 in Review
75 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Alto Neuroscience (ANRO) for Q3 2024, worth a combined $265M — up 34% from $199M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new ANRO positions and 5 closed out — a net gain of 17 holders — while 36 added to existing stakes and 9 trimmed.
The largest buyer was BlackRock, adding an estimated $10.7M. The largest seller was Artal Group, exiting entirely with an estimated $3.74M sold.
- 75 institutional investors held Alto Neuroscience (ANRO) as of Q3 2024, up from 58 in Q2 2024.
- Funds reported $265M of Alto Neuroscience stock for Q3 2024, up 34% quarter-over-quarter.
- 22 funds opened new Alto Neuroscience positions in Q3 2024 and 5 closed out, a net change of +17 holders.
- The largest Alto Neuroscience buyer in Q3 2024 was BlackRock, an estimated $10.7M added.
- The largest Alto Neuroscience seller in Q3 2024 was Artal Group, an estimated $3.74M sold.
Based on aggregated 13F filings for Q3 2024.